Does anyone worry at all about Abbott splitting up and what the impact will be on Neurocrine?
I sure would like to see the Elagolix trial get underway in endo. The uterine fibroids study launched but it's tiny. I'm looking forward to the update this Thursday. We need to get a better idea of when this trial will launch.
I do see buyout potential down the road because of the pipeline synergy. But we would need to see good results out of NBIX's cardio and CNS assets as this overlaps well with Abbott. I think there is a lot of pending Phase 2 data that will move this up or down a bit.